Trials / Conditions / Indolent B-cell Lymphoma

Indolent B-cell Lymphoma

7 registered clinical trials studyying Indolent B-cell Lymphoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting As Indolent NCT06822829	Azienda USL Reggio Emilia - IRCCS	—
Not Yet Recruiting	A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma NCT06343935	Shanghai YingLi Pharmaceutical Co. Ltd.	Phase 4
Completed	Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL NCT03019666	Masonic Cancer Center, University of Minnesota	Phase 1
Completed	p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid NCT02846935	Yogen Saunthararajah	EARLY_Phase 1
Completed	Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infe NCT02836925	Fondazione Italiana Linfomi - ETS	Phase 2
Completed	A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies NCT01805375	Cancer Research UK	Phase 1
Completed	High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas NCT00895661	Massachusetts General Hospital	Phase 2